Larotrectinib: First Global Approval

Larotrectinib (VITRAKVI ® ) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2019-02, Vol.79 (2), p.201-206
1. Verfasser:	Scott, Lesley J.
Format:	Artikel
Sprache:	eng
Schlagworte:	AdisInsight Report Agreements Cancer therapies Collaboration Drug dosages Enzyme inhibitors FDA approval Gene fusion Internal Medicine Kinases Medicine Medicine & Public Health Metastases Metastasis Morbidity Mutation Oncology Oral administration Patients Pharmacology/Toxicology Pharmacotherapy Protein-tyrosine kinase receptors Proteins Solid tumors Surgery Tropomyosin Tumors Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!